Major study tracks Real-World MG care in china

NCT ID NCT06700616

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 1,200 people with myasthenia gravis (MG) across China to understand how the disease is treated in real-world clinics. Researchers will track symptoms, daily living abilities, quality of life, and healthcare use every 6 months until 2027. The goal is to learn more about current treatments and patient outcomes, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS

Contacts and locations

Locations

Research Site

Beijing, China
Research Site

Chengdu, China
Research Site

Fuzhou, China
Research Site

Guangzhou, China
Research Site

Guiyang, China
Research Site

Harbin, China
Research Site

Hebei, China
Research Site

Henan, China
Research Site

Inner Mongolia, China
Research Site

Jiangsu, China
Research Site

Lanzhou, China
Research Site

Nanning, China
Research Site

Qingdao, China
Research Site

Taiyuan, China
Research Site

Tianjin, China
Research Site

Ürümqi, China
Research Site

Wenzhou, China
Research Site

Wuhan, China
Research Site

Xi'an, China
Research Site

Yinchuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.